Some personal news….after 6 great years @LurieCancer I joined @columbiacancer as director of the lymphoma program. I am thrilled to be working with an exceptional group of clinical reasearchers and scientists to advance the understanding and treatment of lymphoma.
#lymsm
Transcription factors don’t fail in MDS—they’re misdirected.
Today in Blood, we show how loss of STAG2 rewires chromatin accessibility to redirect GATA1 and alter blood cell fate.
https://t.co/zlpMlz1St3
Duvelisib Induces Deep Responses in PTCL: Final Results of the Phase 2 PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma | Journal of Clinical Oncology https://t.co/utzDvdDSrs
As more people live longer during and after cancer, doctors are turning their attention to the heart. ❤️🩹
@ColumbiaMed cardio-oncologist Dr. Jayant K. Raikhelkar discusses the growing field helping manage long-term heart effects of cancer treatments. https://t.co/5woMl3XE2N
We're delighted to welcome Dr. Jennifer Amengual as a new Associate Editor for Blood Neoplasia! Dr. Amengual is an Associate Professor of Medicine at @columbiamed and a physician-scientist whose research focuses on developing targeted therapies for patients with lymphoma.
CONGRESS | #SOHO2025 | PRESENTATION
Suzanne Lentzsch @SLentzsch@columbiacancer discussed novel approaches and therapies for the treatment of #amyloidosis. A dFLC <10mg/L is associated with the best outcomes, SoC therapy is Dara-VCd for all patients, and venetoclax for patients with t(11;14). Future directions may include BCMA-directed ADCs, BiTEs, and CAR T.
Follow our live feed for more updates: https://t.co/JmRGgBYAtN
#myeloma #mmsm #MultipleMyeloma
ILC is biologically distinct yet often treated like IBC-NST. Dr. Massimo Cristofanilli (@WeillCornell) shows genomic/transcriptomic profiling reveals enrichment in actionable mutations (PIK3CA, ERBB2) & unique PAM50 subtypes #DAVABreast
Dr. Seda Tolu @Columbia presented the combination of JAK inhibitor Ruxolitinib and ICI Pembrolizumab for treating 9p-amplified lymphomas. The regimen enhances apoptosis and T-cell infiltration, while reducing MDSCs and MYC expression in 9p⁺ lymphomagenesis. #DAVAHeme
The Big Apple brought big insights this weekend at #MXH25 🍎🩸 The energy was electric, the debates were sharp, and the NYC vibes were unmatched.
See you next year for more insights and more Medical Crossfire. 🔥 https://t.co/4Hn67EMMuT #gotoPER@Dr_AmerZeidan@szusmani@bpromd
Results from 4 pivotal phase 3 trials (MIDAS, PERSEUS, IsKIA, ADVANCE) representing current thinking on the role of ASCT in NDMM, masterfully summarized and contextualized by @SLentzsch! #ASCO25#MYELOMA#MRD@columbiacancer
🗽 Big debates. Bold insights. Live in New York.
Join us for the 9th Annual #MXH25 — a one-day, fast-paced event where experts tackle today’s most pressing challenges in hematologic cancer.
HCPs save 75% with code MXH75: https://t.co/gc6kqyFJEH
@bpromd@szusmani@Dr_AmerZeidan https://t.co/vZoxzWPvuA
Start spreadin’ the news… we’re headed to New York for the 9th Annual Live Medical Crossfire®: Hematologic Malignancies!
Join @bpromd@szusmani@Dr_AmerZeidan for expert-led debates and real-time insights!
🗽Get 75% off HCP registration with code MXH75 https://t.co/gc6kqyFJEH